Chronic GVHD characteristics
| Characteristic . | ECP, n = 48 . | Control, n = 47 . |
|---|---|---|
| Corticosteroid status, n (%)* | ||
| Corticosteroid-dependent | 28 (58) | 25 (53) |
| Corticosteroid-refractory | 7 (15) | 5 (11) |
| Corticosteroid-intolerant | 13 (27) | 17 (36) |
| Median days from transplantation to cGVHD (range) | 140 (69-637) | 129 (70-1389) |
| Median days from cGVHD to randomization (range)† | 569 (35-2743) | 630 (1-2253) |
| Onset type of cGVHD, n (%) | ||
| Progressive | 28 (58) | 25 (53) |
| Quiescent | 5 (10) | 6 (13) |
| de novo | 15 (32) | 16 (34) |
| Severity of cGVHD, n (%) | ||
| Limited | 3 (6) | 3 (6) |
| Extensive | 45 (94) | 44 (94) |
| Total Skin Score (TSS) at baseline, median (range) | 9.4 (0.6-23.6) | 9.2 (1.0-20.7) |
| Extracutaneous GVHD involvement, n (%) | ||
| Ocular | 27 (56.3) | 28 (59.6) |
| Gastrointestinal | 2 (4.2) | 9 (19.1) |
| Liver | 14 (29.2) | 14 (29.8) |
| Lung | 9 (18.8) | 7 (14.9) |
| Oral mucosa | 30 (62.5) | 30 (63.8) |
| Joints | 18 (37.5) | 16 (34) |
| Median duration (wks) of corticosteroid usage for cGVHD before study entry (range) | 50 (2.7-426) | 55 (1.9-319) |
| Median daily total oral corticosteroid dose (mg) at baseline (range) | 16 (4-64) | 20 (3.3-60) |
| Concurrent immunosuppressive medication at baseline, n (%) | ||
| Mycophenolate mofetil | 26 (54) | 26 (55) |
| Cyclosporin A | 24 (50) | 28 (60) |
| FK-506 | 11 (23) | 6 (13) |
| Baseline platelet count < 100 000/μL, n (%) | 5 (10.4) | 6 (12.8) |
| Characteristic . | ECP, n = 48 . | Control, n = 47 . |
|---|---|---|
| Corticosteroid status, n (%)* | ||
| Corticosteroid-dependent | 28 (58) | 25 (53) |
| Corticosteroid-refractory | 7 (15) | 5 (11) |
| Corticosteroid-intolerant | 13 (27) | 17 (36) |
| Median days from transplantation to cGVHD (range) | 140 (69-637) | 129 (70-1389) |
| Median days from cGVHD to randomization (range)† | 569 (35-2743) | 630 (1-2253) |
| Onset type of cGVHD, n (%) | ||
| Progressive | 28 (58) | 25 (53) |
| Quiescent | 5 (10) | 6 (13) |
| de novo | 15 (32) | 16 (34) |
| Severity of cGVHD, n (%) | ||
| Limited | 3 (6) | 3 (6) |
| Extensive | 45 (94) | 44 (94) |
| Total Skin Score (TSS) at baseline, median (range) | 9.4 (0.6-23.6) | 9.2 (1.0-20.7) |
| Extracutaneous GVHD involvement, n (%) | ||
| Ocular | 27 (56.3) | 28 (59.6) |
| Gastrointestinal | 2 (4.2) | 9 (19.1) |
| Liver | 14 (29.2) | 14 (29.8) |
| Lung | 9 (18.8) | 7 (14.9) |
| Oral mucosa | 30 (62.5) | 30 (63.8) |
| Joints | 18 (37.5) | 16 (34) |
| Median duration (wks) of corticosteroid usage for cGVHD before study entry (range) | 50 (2.7-426) | 55 (1.9-319) |
| Median daily total oral corticosteroid dose (mg) at baseline (range) | 16 (4-64) | 20 (3.3-60) |
| Concurrent immunosuppressive medication at baseline, n (%) | ||
| Mycophenolate mofetil | 26 (54) | 26 (55) |
| Cyclosporin A | 24 (50) | 28 (60) |
| FK-506 | 11 (23) | 6 (13) |
| Baseline platelet count < 100 000/μL, n (%) | 5 (10.4) | 6 (12.8) |